Junko Matsuzaki to Ovarian Neoplasms
This is a "connection" page, showing publications Junko Matsuzaki has written about Ovarian Neoplasms.
Connection Strength
3.186
-
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.
Score: 0.528
-
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer. Oncoimmunology. 2022; 11(1):2020983.
Score: 0.521
-
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015 Oct 08; 5:14896.
Score: 0.338
-
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27; 107(17):7875-80.
Score: 0.231
-
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother. 2008 Aug; 57(8):1185-95.
Score: 0.199
-
Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer. Cancer Cell. 2022 05 09; 40(5):452-454.
Score: 0.133
-
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10).
Score: 0.128
-
GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. Clin Cancer Res. 2021 10 15; 27(20):5536-5545.
Score: 0.126
-
Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight. 2019 03 07; 4(5).
Score: 0.107
-
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017 06; 145(3):420-425.
Score: 0.094
-
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol. 2016 07; 142(1):158-162.
Score: 0.088
-
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015 Sep 29; 6(29):27359-77.
Score: 0.084
-
Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015; 10(3):237-46.
Score: 0.080
-
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 2014; 9(8):e104099.
Score: 0.078
-
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014 Jan; 2(1):37-49.
Score: 0.075
-
CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 2012 Sep 01; 72(17):4351-60.
Score: 0.068
-
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5797-802.
Score: 0.066
-
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009 Jul 01; 69(13):5498-504.
Score: 0.054
-
Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J Immunother. 2009 Feb-Mar; 32(2):101-8.
Score: 0.053
-
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008 Oct 07; 105(40):15505-10.
Score: 0.052
-
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007 Jul 31; 104(31):12837-42.
Score: 0.048
-
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol. 2012 Apr 15; 188(8):3851-8.
Score: 0.017
-
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PLoS One. 2011; 6(8):e23651.
Score: 0.016